**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Prem Soman, University of Pittsburgh Medical Center, Pittsburgh, PA
somanp@upmc.edu

**Main Body of the Abstract**
BACKGROUND: Identifying markers of therapeutic futility may help to channel expensive therapy and finite resources appropriately.
METHODS: We sought to determine the predictors of all-cause death occurring within 12 months of initiating tafamidis therapy using real-world, individual-level patient data pooled from 5 expert amyloid centers (Cleveland Clinic Foundation, University of Pittsburgh, Columbia University, Saint Luke’s Mid-America Heart Institute, Oregon Health Sciences University)
RESULTS: Of 624 patients studied, 65 (11%) died within 12 months of starting tafamidis therapy. Patients who died were older [age (median, IQR) 79, 73-85 vs. 77, 71-83 p =0.037)] had a greater prevalence of NYHA III (69.7% vs 29.7%, p< 0.001), NYHA IV
(7.7% vs 0.2%, p< 0.001), hypertension (81.5% vs 69.2% p=0.054), lower LVEF (43.5% vs 55%, p< 0.001), higher NAC stage (p<0.001), and higher diuretic usage (furosemide score 3, 38.5% vs 11.3%, p<0.001). Sex, race, diabetes mellitus, concomitant CAD, and variant ATTR were not predictive of early mortality. In multivariable analysis, NYHA class III or IV, a high daily diuretic dose, LVEF, and NAC stage >0 were independently predictive of early mortality.
CONCLUSION: Routinely obtained clinical parameters can predict early mortality after tafamidis initiation in ATTR amyloid cardiomyopathy. Further analysis is being performed to determine the feasibility of a clinical score to predict the futility of tafamidis therapy in these patients.



Predictors of early mortality after initiation of tafamidis therapy PC144 (#538)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.